Compare Hilton Hotels Corporation Common Stock (HLT) vs Iovance Biotherapeutics Inc. Common Stock (IOVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? Hilton Hotels Corporation Common Stock trades at $327.15 (market cap $72.76B), while Iovance Biotherapeutics Inc. Common Stock trades at $14.6 (market cap $6.04B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 12× Iovance Biotherapeutics Inc. Common Stock's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hilton Hotels Corporation Common Stock for 138 Days and Iovance Biotherapeutics Inc. Common Stock for 0 Days on average.
| HLT | IOVA | |
|---|---|---|
Market Cap | $72.76B | $6.04B |
Volume | 1,148,634 | 14,805,993 |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $14.82 |
52-Week Low | $256.96 | $1.81 |
Typical Hold Time | 138 Days | 0 Days |
Enterprise Value | $85.78B | $5.97B |
Dividend Yield | 0.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide (HLT) trades at $326.56, up 1.89% with a bullish technical outlook. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth has been steady, reaching $12.04B in 2025, though valuation multiples like P/E of 47.47 appear elevated. Analyst consensus is strongly positive with 57% buy ratings and a $348.11 price target, while institutional investors have been increasing positions.
The outlook remains favorable given Hilton's strong brand positioning and global travel recovery, but risks include high debt levels and sensitivity to economic cycles. With technical indicators bullish and fundamental growth intact, HLT offers growth potential though current valuation requires careful monitoring of earnings delivery.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →
